CPT1A and rheumatoid arthritis: The present findings indicate that target CPT1A and fatty acid metabolism in peripheral CD14+ monocytes could be a therapeutic strategy to inhibit OCP multinucleation, which may be a promising therapeutic target for bone loss in patients with RA.